Thursday, 13 August 2020

Hansoh announces strategic collaboration with EQRx for almonertinib

24 July 2020 | News

The Partnership will aim to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC).

Shanghai-based Hansoh Pharmaceutical Group Company Ltd., a leading biopharmaceutical company has recently announced a strategic collaboration and licensing agreement for almonertinib with US based EQRx™, a biopharmaceutical company committed to making innovative medicines at dramatically lower prices for the benefit of people and society.

Under the terms of the agreement, EQRx will be responsible for the development and commercialization of almonertinib in the United States, Europe, Japan, and all other global markets outside of Greater China, and Hansoh Pharma will continue its development and commercialization of almonertinib in Greater China.

EQRx and Hansoh will seek to jointly conduct global studies to further expand the potential of almonertinib as a monotherapy and in combination therapy settings. Hansoh will receive approximately $100 million in upfront payment and development and regulatory milestones, with additional undisclosed commercial milestones as well as royalty payments.

In March 2020, almonertinib received marketing authorization from the NMPA in China for second-line treatment in patients with EGFR T790M mutation-positive NSCLC. Almonertinib provides a highly efficacious treatment option with a favorable safety profile for advanced NSCLC patients.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls